Q-omics provides the consensus-scored SMTN profile across patient tissues and cancer cell-line models. SMTN expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SMTN is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, SMTN protein abundance shows 21,704 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight KIRP, HNSC, and UCEC as cancer lineages where SMTN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMTN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMTN survival associations across molecular data types. SMTN RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMTN RNA expression–survival associations across cancer types. High SMTN expression shows unfavorable associations in KIRP, ACC, MESO, LIHC, CESC and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SMTN RNA expression.
This table summarizes SMTN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SMTN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMTN shows lower tumor expression in BLCA, UCEC and BRCA and higher tumor expression in HNSC, KIRC and LIHC. The HNSC box plot shows higher SMTN RNA expression in tumor versus normal tissue (log2 FC = +1.875, t-test p < 0.001).
This table shows molecular features associated with SMTN in patient tissues and cancer cell lines. In patient samples, SMTN shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, SMTN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BONE.
